The effectiveness of adjuvant PD-1 inhibitors in patients with surgically resected stage III/IV acral melanoma

Basit Öğe Kaydı
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021
dc.contributor.authorArak, Hacı
dc.contributor.authorErkılıç, Suna
dc.contributor.authorYaşlıkaya, Şendağ
dc.contributor.authorMocan, Eda Eylemer
dc.contributor.authorAktaş, Gökmen
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorÖzdemir, Melek
dc.contributor.authorSemiz, Hüseyin Salih
dc.contributor.authorÖzalp, Faruk Recep
dc.contributor.authorSever, Özlem Nuray
dc.contributor.authorAkdağ, Goncagül
dc.contributor.authorAğaoğlu, Ahmet Burak
dc.contributor.authorÖzçelik, Melike
dc.contributor.authorSarı, Murat
dc.contributor.authorArcagök, Murat
dc.contributor.authorAnik, Hicran
dc.contributor.authorYayla, Saziye Burçak
dc.contributor.authorSever, Nadiye
dc.contributor.authorAcar, Fatma Pınar
dc.contributor.authorBayrakcı, İsmail
dc.contributor.authorTurhal, Serdar
dc.contributor.authorAyhan, Murat
dc.contributor.authorKuş, Tulay
dc.date.accessioned2025-04-18T09:44:32Z
dc.date.available2025-04-18T09:44:32Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractOur aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare the other adjuvant treatments in patients with surgically resected stage III or IV acral melanoma. This study is a multicenter, retrospective analysis. We included 114 patients with stage III or IV acral malignant melanoma who underwent surgery within the past 10 years. We analyzed the effect of adjuvant programmed cell death protein-1 inhibitors on disease-free survival (DFS). The mean follow-up was 40 months, during which 69 (59.5%) patients experienced recurrence. Among the participants, 64 (56.1%) received systemic adjuvant therapy. Specifically, 48.4% received anti-PD-1 therapy, 29.7% received interferon, 14.1% received tezozolomide, and 7.8% received B-Raf proto-oncogene/mitogen-activated protein kinase inhibitors. Patients who received adjuvant therapy had a median DFS of 24 (10.9-37.2) months, whereas those who did not receive adjuvant therapy had a median DFS of 15 (9.8-20.2) months. Multivariate analysis for DFS revealed that the receipt of adjuvant therapy and lymph node metastasis stage were independent significant parameters (P = 0.021, P = 0.018, respectively). No statistically significant difference was observed for DFS between programmed cell death protein-1 inhibitor treatment and other adjuvant treatments. Regarding overall survival (OS), patients who received adjuvant treatment had a median OS of 71 (30.4-111.7) months, whereas those who did not receive adjuvant treatment had a median OS of 38 (16.7-59.3; P = 0.023) months. In addition, there were no significant differences in OS observed between various adjuvant treatment agents (P = 0.122). In our study, we have shown that adjuvant therapy had a positive effect on both DFS and OS in patients with stages III-IV acral melanoma who underwent curative intent surgery. Notably, we found no significant differences between anti-PD-1 therapy and other adjuvant therapies.
dc.identifier.citationArak, H., Erkiliç, S., Yaslikaya, Ş., Mocan, E. E., Aktaş, G., Özdemir, M., ... & Kuş, T. (2024). The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma. Journal of Immunotherapy, 47(5), 182-189.
dc.identifier.doi10.1097/CJI.0000000000000508
dc.identifier.endpage189
dc.identifier.issn1524-9557
dc.identifier.issn1537-4513
dc.identifier.issue5
dc.identifier.pmid38333962
dc.identifier.scopus2-s2.0-85192677523
dc.identifier.scopusqualityQ2
dc.identifier.startpage182
dc.identifier.urihttp://dx.doi.org/10.1097/CJI.0000000000000508
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6843
dc.identifier.volume47
dc.identifier.wosWOS:001277944000005
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKılıçkap, Saadettin
dc.institutionauthoridSaadettin Kılıçkap / 0000-0003-1637-7390
dc.language.isoen
dc.publisherLippincott williams & wilkins
dc.relation.ispartofJournal of immunotherapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAcral Malignant Melanoma Adjuvant Therapy
dc.subjectNivolumab
dc.titleThe effectiveness of adjuvant PD-1 inhibitors in patients with surgically resected stage III/IV acral melanoma
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
the_effectiveness_of_adjuvant_pd_1_inhibitors_in.4.pdf
Boyut:
219.74 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu